Novartis Cholesterol Drug Fails to Reduce Heart Attacks and Strokes
Novartis' experimental cholesterol drug pelacarsen failed to reduce heart attacks or strokes in a major clinical trial, despite significantly lowering lipoprotein(a) levels. The Horizon trial involved 8,322 participants and was presented at an American Heart Association meeting. Novartis has no further plans for pelacarsen, but other treatments targeting Lp(a) are under investigation.
How this was made
The 30-second read
Why it matters
The failure undermines expectations for Lp(a) lowering as a cardiovascular risk‑reduction strategy and may delay related drug launches.
Market read
First‑report of a major negative Phase 3 outcome for a large‑cap pharma, likely prompting a sell‑off in NVS and influencing the broader cardiovascular‑therapy sector.
What to watch
The trial still demonstrated a 78% Lp(a) reduction; future combination therapies or different patient populations may succeed.
Background
Novartis presented Horizon trial results at the American Heart Association meeting, showing no reduction in heart attacks or strokes despite large Lp(a) lowering.
Ticker impact
Novartis' pelacarsen trial failed to show cardiovascular benefit, likely pressuring the stock.
likely downside as the market prices in the lack of efficacy data
First‑report of a major Phase 3 failure for a large‑cap pharma; investors typically sell on such setbacks.
Market effects
Sets back the Lp(a) therapeutic pipeline, may shift focus to RNA‑based approaches from competitors.
European and US biotech stocks with similar antisense programs could see modest pressure.
Highlights challenges in cardiovascular drug development, affecting investor sentiment across the pharma sector.
Counterpoint
If the trial data were misinterpreted, a later sub‑analysis could revive interest, offering a buying opportunity on dip.
Key entities
- CompanyNovartis
Swiss pharmaceutical giant conducting the pelacarsen trial.
- DrugPelacarsen
Antisense oligonucleotide targeting lipoprotein(a).
